Lipocine (NASDAQ:LPCN) Shares Pass Above 50 Day Moving Average – Should You Sell?

Lipocine Inc. (NASDAQ:LPCN)’s stock price passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $2.31 and traded as high as $2.37. Lipocine shares last traded at $2.29, with a volume of 30,358 shares.

Analyst Ratings Changes

LPCN has been the subject of a number of research analyst reports. HC Wainwright restated a “neutral” rating on shares of Lipocine in a report on Monday, April 6th. Wall Street Zen upgraded shares of Lipocine from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings lowered shares of Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $15.00.

Lipocine Trading Down 2.6%

The business has a 50-day moving average price of $2.31 and a 200 day moving average price of $5.33. The stock has a market cap of $18.38 million, a PE ratio of -1.19 and a beta of 0.44.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The firm had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.16 million. Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%. On average, equities analysts predict that Lipocine Inc. will post -1.91 earnings per share for the current year.

Institutional Trading of Lipocine

Several hedge funds and other institutional investors have recently modified their holdings of the business. Citadel Advisors LLC bought a new stake in Lipocine during the 3rd quarter valued at $41,000. Jane Street Group LLC bought a new position in shares of Lipocine in the fourth quarter worth $85,000. Dimensional Fund Advisors LP grew its position in shares of Lipocine by 57.5% in the first quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock valued at $153,000 after purchasing an additional 6,982 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in shares of Lipocine in the first quarter valued at $185,000. Finally, Renaissance Technologies LLC raised its stake in shares of Lipocine by 3.6% during the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after purchasing an additional 1,300 shares during the period. Institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.